Evidence map›Paper›PMID 35646540›Full record

ReviewActa pharmaceutica Sinica. B2022

Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases.

Baoyi Guan, Jinlin Tong, Haiping Hao, Zhixu Yang, Keji Chen, Hao Xu, Anlu Wang

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 1 pooled it
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 1 synthesis or guideline pooled it, 173 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Cholestasis in Alcohol-Associated Liver Disease.The American journal of pathology · 2026
    Review
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Baoyi GuanXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Jinlin TongXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Haiping HaoState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Zhixu YangXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Keji ChenXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Hao XuXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Anlu WangXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiometabolic disease (CMD), characterized with metabolic disorder triggered cardiovascular events, is a leading cause of death and disability. Metabolic disorders trigger chronic low-grade inflammation, and actually, a new concept of metaflammation has been proposed to define the state of metabolism connected with immunological adaptations. Amongst the continuously increased list of systemic metabolites in regulation of immune system, bile acids (BAs) represent a distinct class of metabolites implicated in the whole process of CMD development because of its multifaceted roles in shaping systemic immunometabolism. BAs can directly modulate the immune system by either boosting or inhibiting inflammatory responses

Indexed as

AS, atherosclerosisASBT, apical sodium-dependent bile salt transporterBAs, bile acidsBile acidBSEP, bile salt export pumpBSH, bile salt hydrolasesCA, cholic acidcAMP, cyclic adenosine monophosphateCAR, constitutive androstane receptorCardiometabolic diseasesCCs, cholesterol crystalsCDCA, chenodeoxycholic acidCMD, cardiometabolic diseaseCVDs, cardiovascular diseasesCYP7A1, cholesterol 7 alpha-hydroxylaseCYP8B1, sterol 12α-hydroxylaseDAMPs, danger-associated molecular patternsDCA, deoxycholic acidDCs, dendritic cellsERK, extracellular signal-regulated kinaseFA, fatty acidsFFAs, free fatty acidsFGF, fibroblast growth factorFMO3, flavin-containing monooxygenase 3FXR, farnesoid X receptorGLP-1, glucagon-like peptide 1HCA, hyocholic acidHDL, high-density lipoproteinHFD, high fat dietHNF, hepatocyte nuclear receptorIL, interleukinIR, insulin resistanceJNK, c-Jun N-terminal protein kinaseLCA, lithocholic acidLDL, low-density lipoproteinLDLR, low-density lipoprotein receptorLPS, lipopolysaccharidemTOR, mammalian target of rapamycinNAFLD, non-alcoholic fatty liver diseaseNASH, nonalcoholic steatohepatitisNF-κB, nuclear factor-κBNLRP3, NLR family pyrin domain containing 3Nuclear receptorsOCA, obeticholic acidox-LDL, oxidated low-density lipoproteinPKA, protein kinase APPARα, peroxisome proliferator-activated receptor alphaPXR, pregnane X receptorRCT, reverses cholesterol transportationROR, retinoid-related orphan receptorS1PR2, sphingosine-1-phosphate receptor 2SCFAs, short-chain fatty acidsSHP, small heterodimer partnerSystemic immunometabolismTGR5, takeda G-protein receptor 5TG, triglycerideTherapeutic opportunitiesTLR, toll-like receptorTMAO, trimethylamine N-oxideUDCA, ursodeoxycholic acidVDR, vitamin D receptor

Identifiers

PMID35646540
PMCPMC9136572
OpenAlexW4200521334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.